Low dose m-BACOD regimen.
| * No longer employed, although part of the original regimen. | |
| Bleomycin | 4 mg/m2 day 1 IV |
| Doxorubicin | 25 mg/m2 day 1 IV |
| Cyclophosphamide | 300 mg/m2 day 1 IV |
| Vincristine sulfate | 1.4 mg/m2 day 1 IV (not to exceed 2 mg) |
| Dexamethasone | 3 mg/m2 days 1–5 PO |
| Methotrexate (MTX) | 500 mg/m2 day 15 IV, with folinic acid rescue, 25 mg PO q 6h x 4, beginning 6 hr after completion of MTX |
| Cytosine arabinoside | 50 mg days 1, 8, 21, 28 intrathecally |
| * Helmet-field radiotherapy | 2400 cGy with marrow involvement; 4000 cGy with known central nervous system involvement |
| * Zidovudine | 200 mg q4h for 1 yr, starting after chemotherapy |
| Total treatment | 4–6 cycles at 28-day intervals |
| * No longer employed, although part of the original regimen. | |
| Bleomycin | 4 mg/m2 day 1 IV |
| Doxorubicin | 25 mg/m2 day 1 IV |
| Cyclophosphamide | 300 mg/m2 day 1 IV |
| Vincristine sulfate | 1.4 mg/m2 day 1 IV (not to exceed 2 mg) |
| Dexamethasone | 3 mg/m2 days 1–5 PO |
| Methotrexate (MTX) | 500 mg/m2 day 15 IV, with folinic acid rescue, 25 mg PO q 6h x 4, beginning 6 hr after completion of MTX |
| Cytosine arabinoside | 50 mg days 1, 8, 21, 28 intrathecally |
| * Helmet-field radiotherapy | 2400 cGy with marrow involvement; 4000 cGy with known central nervous system involvement |
| * Zidovudine | 200 mg q4h for 1 yr, starting after chemotherapy |
| Total treatment | 4–6 cycles at 28-day intervals |